NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces
the publication of an editorial featuring PreveCeutical Medical Inc. (OTCQB:PRVCF) (CSE:PREV) (FSE:18H), a health
sciences company and client of NNW that develops innovative preventive therapies utilizing organic and nature identical products.
To view the full publication, titled “Fast-Growing Cannabis Industry Drives Biotech Research, Innovative Medical Therapy
Development,” visit: LINK
PreveCeutical has a product, CELLB9®, an oral dilute solution utilizing select peptides from the blue scorpion, found only in
the Caribbean region. PreveCeutical’s “Nature Identical” research team is building on proprietary chemistry to produce controlled
venom peptides that it hopes will be able to halt the progression of cancers, while also exploring the peptides’ potential in
responding to other medical concerns related to pain management, metabolic disorders, cancers, cardiovascular conditions and
infectious diseases.
PreveCeutical is currently in a joint venture with Sports 1 Marketing to focus on the therapeutic potential of the Natural
Identical venom’s peptides and proteins to treat mild brain injury concussions in athletes.
The company is also currently working with four leading Australian research centers to develop a curative therapy for diabetes
and obesity. This is a novel four-year program selectively targeting the gene that encodes for the protein PTP-1B, implicated and
over-expressed in both Type-2 diabetes and obesity.
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and
development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel
platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of
various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and
oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical
sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals
extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information visit www.PreveCeutical.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)
NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release
services from NetworkWire, (4) social media distribution and optimization services, and (5) a full array of
corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a
wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more
than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings
its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more
information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever
published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof.
In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
